The balance sheet reflects a precarious financial state, with total assets contracting to $3.3 million and shareholder equity falling into negative territory at -$881.0K as of 2026Q1.
| Total Current Assets | 3.04M | 5.58M | 20.52M | 17.63M | 36.88M | 66.64M | 60.67M | 84.53M | 39.89M | 8.47M |
| Cash & Short-Term Investments | 1.17M | 4.96M | 17.81M | 14.91M | 33.33M | 62.1M | 56.33M | 82.41M | 39.66M | 8.15M |
| Cash Only | 1.17M | 4.96M | 17.81M | 14.91M | 31.33M | 62.1M | 36.48M | 72.41M | 8.6M | 6.99M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 2M | 0 | 19.85M | 10M | 31.05M | 1.15M |
| Accounts Receivable | 0 | 0 | 1.17M | 574K | 567K | 888K | 0 | 244K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -29K | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.88M | 620K | 254K | 1.52M | 1.49M | 1.4M | 2.25M | 50K | 0 | 0 |
| Total Non-Current Assets | 208K | 64.66M | 22.71M | 7.4M | 8.65M | 11.35M | 9.7M | 7.59M | 5.44M | 5.52M |
| Property, Plant & Equipment | 0 | 0 | 10.5M | 7.4M | 8.65M | 9.83M | 6.66M | 3.03M | 887K | 960K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 208K | 208K | 12.05M | 0 | 0 | 1.52M | 3.04M | 4.56M | 4.56M | 0 |
| Long-Term Investments | 322K | 0 | 161K | 0 | 0 | 0 | 0 | 0 | 70.88M | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5K | -70.88M | 4.56M |
| Total Assets | 3.25M | 70.24M | 43.23M | 25.03M | 45.53M | 77.99M | 70.36M | 92.12M | 45.33M | 13.99M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -131.33% | 62.47% | 72.73% | -45.03% | -41.62% | 10.84% | -23.62% | 103.22% | 224.02% | - |
| Total Current Liabilities | 2.45M | 6.38M | 8.27M | 11.18M | 7.94M | 11.04M | 7.16M | 6.22M | 1.64M | 1.46M |
| Accounts Payable | 720K | 3.12M | 1.88M | 1.38M | 820K | 2.79M | 2.32M | 3.25M | 56.58K | 1K |
| Days Payables Outstanding | 255.68 | 389.73 | 380.99 | 578.72 | - | - | - | - | 98.34 | 3.84 |
| Short-Term Debt | 0 | 1.44M | 0 | 5.79M | 4.28M | 0 | 0 | 375K | 0 | 40K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 28K | 242K | 1.98M | 65K | 60K | 58K | -40K |
| Other Current Liabilities | 1.73M | 1.82M | 1.48M | -28K | 0 | 0 | 0 | 756K | 581K | 1.42M |
| Current Ratio | 1.24x | 0.87x | 2.48x | 1.58x | 4.65x | 6.03x | 8.47x | 13.58x | 24.34x | 5.81x |
| Quick Ratio | 1.24x | 0.87x | 2.48x | 1.58x | 4.65x | 6.03x | 8.47x | 13.58x | 24.35x | 5.81x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.69M | 65.16M | 10.82M | 10.77M | 16.55M | 19.41M | 5.73M | 1.44M | 889K | 1M |
| Long-Term Debt | 0 | 0 | 0 | 5.4M | 10.59M | 14.41M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 13.43M | 0 | 8.45M | 3.24M | 3.8M | 4.79M | 5.03M | 856K | 0 | 0 |
| Deferred Tax Liabilities | 64.46M | 64.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.69M | 706K | 2.36M | 155K | 188K | 215K | 701K | 585K | 889K | 1M |
| Total Liabilities | 4.13M | 71.54M | 19.09M | 21.95M | 24.49M | 30.45M | 12.89M | 7.67M | 2.53M | 2.46M |
| Total Debt | 0 | 1.44M | 9.58M | 15.09M | 19.36M | 20.02M | 5.89M | 1.23M | 0 | 40K |
| Net Debt | -1.17M | -3.52M | -8.23M | 185K | -11.97M | -42.08M | -30.58M | -71.18M | -8.6M | -6.95M |
| Debt / Equity | -0.00x | - | 0.40x | 4.90x | 0.92x | 0.42x | 0.10x | 0.01x | - | 0.00x |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.03x | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -57.10x | -35.78x | -5.36x | -9.85x | -12.65x | -50.73x | -4322.57x | -346.98x | - | - |
| Total Equity | -881K | -1.3M | 24.15M | 3.08M | 21.04M | 47.53M | 57.47M | 84.46M | 42.8M | 11.53M |
| Equity Growth % | -311.45% | -105.39% | 683.77% | -85.36% | -55.74% | -17.29% | -31.95% | 97.31% | 271.23% | - |
| Book Value per Share | -0.00 | -0.00 | 0.03 | 1.14 | 13.39 | 34.72 | 47.35 | 70.91 | 40.62 | 11.13 |
| Total Shareholders' Equity | -881K | -1.3M | 24.15M | 3.08M | 21.04M | 47.53M | 57.47M | 84.46M | 42.8M | 11.53M |
| Common Stock | 7K | 7K | 6K | 3K | 2K | 2K | 2K | 2K | 65.75M | 201 |
| Retained Earnings | -236.04M | -216.9M | -180.7M | -162.97M | -136.8M | -108.48M | -72.26M | -42.17M | -21.61M | -8.89M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | -72.26M | 0 | -21.61M | -1.02K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Critical liquidity and dilution
As reported in financial statements, total assets have plummeted from $81.6 million in 2024Q1 to a mere $3.3 million by 2026Q1, signaling a severe contraction in the company's resource base as it exhausts its remaining capital to fund ongoing clinical development programs.
The consistent decline in total assets over the last ten quarters reflects a business model that is rapidly consuming its financial foundation without achieving commercial milestones. This trajectory suggests that the company is nearing a critical inflection point where operational survival will necessitate immediate and likely dilutive external financing.
According to recent SEC filings, the company's cash position has dwindled to $1.2 million as of 2026Q1, a stark reduction from the $44.1 million reported in 2024Q1, which leaves the firm with an extremely narrow margin for error in its clinical trial execution.
The current ratio of 1.24 indicates that while the company maintains a marginal ability to cover short-term obligations, the absolute cash level is insufficient to support sustained R&D activities. Investors should monitor the company's ability to secure non-dilutive funding, as the current liquidity profile appears highly precarious.
Based on the company's reported figures, shareholder equity has deteriorated into negative territory, reaching -$881.0K in 2026Q1, which underscores the cumulative impact of persistent net losses and the exhaustion of retained earnings over the observed period.
The shift to negative equity is a significant indicator of the financial strain caused by prolonged pre-revenue operations and high R&D burn. This condition often complicates future capital raising efforts and may signal to the market that the company's historical value has been largely eroded by operational costs.
As indicated by the balance sheet data, the company's asset base is increasingly devoid of tangible value, with PPE net dropping to zero by 2026Q1, leaving the firm reliant on intangible assets that may be subject to future impairment risks.
The absence of tangible assets like property, plant, and equipment suggests that the company has little to no collateral value to support traditional debt financing. This reliance on intangible assets, combined with the lack of revenue, makes the balance sheet highly sensitive to any negative clinical trial outcomes or shifts in market sentiment.
Quick answers to the most common questions about buying PHGE stock.
As of 2025, BiomX Inc. (PHGE) had total assets of $70.2M including $5.6M in current assets.
BiomX Inc. (PHGE) carries total debt of $1.4M, offset by $5.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
BiomX Inc. (PHGE) has total shareholders' equity (book value) of $-1.3M ($-0.00 book value per share). Book value represents the net worth of the company belonging to common stock holders.
BiomX Inc. (PHGE) reported a current ratio of 0.87x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.